Advertisement

Reply to: "Ammonia - an old friend with a new area of application"

  • Thomas H. Tranah,
  • María-Pilar Ballester,
  • Juan Antonio Carbonell-Asins,
  • Rajiv Jalan,
  • Debbie L. Shawcross
Published online: October 07, 2022

Is NAFLD a Key Driver of Brain Dysfunction?

  • Leontine Sandforth,
  • Nermeen N. El-Agroudy,
  • Andreas L. Birkenfeld
Published online: October 07, 2022

October 6, 2022

Mitochondrial alterations in fatty liver diseases

  • Bernard Fromenty,
  • Michael Roden
Published online: October 06, 2022
Open Access

October 5, 2022

September 29, 2022

Expert opinion versus meta-analysis: to be or not to be?

  • Calogero Cammà,
  • Marco Enea,
  • Ciro Celsa
Published online: September 29, 2022

September 26, 2022

Reply to: “SEAL: Why was this approach not effective?”

  • Christian Labenz,
  • Frank Lammert,
  • Peter R. Galle
Published online: September 26, 2022

September 23, 2022

LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma

  • Caitlin B. Conboy,
  • Jennifer A. Yonkus,
  • EeeLN H. Buckarma,
  • ...
  • Akhilesh Pandey,
  • Gregory J. Gores,
  • Rory L. Smoot
Published online: September 23, 2022
Open Access

September 21, 2022

Viral protease cleavage of MAVS in genetically modified mice with hepatitis A virus infection

  • Lu Sun,
  • Hui Feng,
  • Ichiro Misumi,
  • ...
  • Dale O. Cowley,
  • Jason K. Whitmire,
  • Stanley M. Lemon
Published online: September 21, 2022

National trends in retreatment of HCV due to reinfection or treatment failure in Australia

  • Joanne M. Carson,
  • Sebastiano Barbieri,
  • Gail V. Matthews,
  • Gregory J. Dore,
  • Behzad Hajarizadeh
Published online: September 21, 2022

Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury

  • Naga Chalasani,
  • Yi-Ju Li,
  • Andrew Dellinger,
  • ...
  • David E. Kleiner,
  • Jay H. Hoofnagle
  • for the Drug Induced Liver Injury Network
Published online: September 21, 2022

Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis

  • Jiří Reiniš,
  • Oleksandr Petrenko,
  • Benedikt Simbrunner,
  • ...
  • Stefan Kubicek,
  • Mattias Mandorfer,
  • Thomas Reiberger
Published online: September 21, 2022
Open Access

A double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study

  • Andrew Fagan,
  • Edith A. Gavis,
  • Mary Leslie Gallagher,
  • ...
  • Michael Fuchs,
  • Leroy Thacker,
  • Jasmohan S. Bajaj
Published online: September 21, 2022

Reverse inflammaging: Long-term effects of HCV cure on biological age

  • Carlos Oltmanns,
  • Zhaoli Liu,
  • Jasmin Mischke,
  • ...
  • Anke R.M. Kraft,
  • Cheng-Jian Xu,
  • Markus Cornberg
Published online: September 21, 2022

Effect of variants in LGP2 on MDA5-mediated activation of interferon response and suppression of hepatitis D virus replication

  • Nadine Gillich,
  • Zhenfeng Zhang,
  • Marco Binder,
  • Stephan Urban,
  • Ralf Bartenschlager
Published online: September 21, 2022
Open Access

September 20, 2022

Severity of systemic inflammation is the main predictor of ACLF and bleeding in individuals with acutely decompensated cirrhosis

  • Alberto Zanetto,
  • Filippo Pelizzaro,
  • Elena Campello,
  • ...
  • Patrizia Burra,
  • Paolo Simioni,
  • Marco Senzolo
Published online: September 20, 2022

Rational development of combination therapies for biliary tract cancers

  • James J. Harding,
  • Danny N. Khalil,
  • Luca Fabris,
  • Ghassan K. Abou-Alfa
Published online: September 20, 2022

September 19, 2022

Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study

  • Masatoshi Kudo,
  • Richard S. Finn,
  • Shukui Qin,
  • ...
  • Kenichi Saito,
  • Corina E. Dutcus,
  • Riccardo Lencioni
Published online: September 19, 2022
Open Access

September 14, 2022

The association between liver fibrosis and cognitive impairment in type 2 diabetes

  • Calum D. Moulton,
  • Emily Staite,
  • Kirsty Winkley,
  • Michael A. Heneghan,
  • Khalida Ismail
Published online: September 14, 2022

Bepirovirsen / GSK3389404: antisense or TLR9 agonists?

  • Andrew Vaillant
Published online: September 14, 2022

In situ detection of vaccine mRNA in the cytoplasm of hepatocytes during COVID-19 vaccine-related hepatitis

  • Loreto Martin-Navarro,
  • Carlos de Andrea,
  • Bruno Sangro,
  • Josepmaria Argemi
Published online: September 14, 2022

Loss of liver function in chronic liver disease: An identity crisis

  • Carmen Berasain,
  • Maria Arechederra,
  • Josepmaria Argemí,
  • Maite G. Fernández-Barrena,
  • Matías A. Avila
Published online: September 14, 2022
Open Access

September 8, 2022

Human duodenal submucosal glands contain a defined stem/progenitor subpopulation with liver-specific regenerative potential

  • Vincenzo Cardinale,
  • Guido Carpino,
  • Diletta Overi,
  • ...
  • Lola M. Reid,
  • Domenico Alvaro,
  • Eugenio Gaudio
Published online: September 08, 2022

September 7, 2022

Evaluation of CirrhoCare® – a digital health solution for home management of individuals with cirrhosis

  • Konstantin Kazankov,
  • Simone Novelli,
  • Devnandan A. Chatterjee,
  • ...
  • Ravi Kumar,
  • Rajiv Jalan,
  • Rajeshwar P. Mookerjee
Published online: September 07, 2022

Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote liver allograft tolerance in humans

  • Tiong Y. Lim,
  • Elena Perpiñán,
  • Maria-Carlota Londoño,
  • ...
  • Marc Martinez-Llordella,
  • Tim Tree,
  • Alberto Sánchez-Fueyo
Published online: September 07, 2022
Open Access

September 5, 2022

Viral clade is associated with severity of symptomatic genotype 3 hepatitis E virus infections in Belgium, 2010–2018

  • Michael Peeters,
  • Julie Schenk,
  • Thomas De Somer,
  • ...
  • Steven Van Gucht,
  • Thomas Vanwolleghem
  • on behalf of the Belgian Association for the Study of the Liver
Published online: September 05, 2022

September 4, 2022

Portal hypertension is a key determinant of the risk for liver-related events in non-alcoholic fatty liver disease

  • Rafael Paternostro,
  • Wilhelmus J. Kwanten,
  • Thomas Reiberger
Published online: September 04, 2022

September 2, 2022

Neutrophil extracellular traps contribute to liver damage and increase defective low-density neutrophils in alcohol-associated hepatitis

  • Yeonhee Cho,
  • Terence Ndonyi Bukong,
  • David Tornai,
  • ...
  • Eleni Kanata,
  • Donna Catalano,
  • Gyongyi Szabo
Published online: September 02, 2022

Pathogenesis of primary liver carcinomas

  • Valérie Paradis,
  • Jessica Zucman-Rossi
Published online: September 02, 2022

Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease

  • Fredrik Åberg,
  • Christopher D. Byrne,
  • Carlos J. Pirola,
  • Ville Männistö,
  • Silvia Sookoian
Published online: September 02, 2022
Open Access

September 1, 2022

Incidence and factors predictive of recurrent thrombosis in people with non-cirrhotic portal vein thrombosis

  • Anna Baiges,
  • Bogdan Procopet,
  • Gilberto Silva-Junior,
  • ...
  • on behalf of REHEVASC,
  • VALDIG,
  • an EASL consortium
Published online: September 01, 2022

August 29, 2022

IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease

  • Jiwoon Park,
  • Yuanyuan Zhao,
  • Fan Zhang,
  • ...
  • Jae U. Jung,
  • Charles M. Rice,
  • Xianfang Wu
Published online: August 29, 2022

August 28, 2022

Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure

  • Julia Dietz,
  • Beat Müllhaupt,
  • Peter Buggisch,
  • ...
  • University Hospitals,
  • Academic Hospitals,
  • Local study sites (private practices), Germany
Published online: August 28, 2022

August 26, 2022

2D and 3D liver models

  • Sarah H. Saxton,
  • Kelly R. Stevens
Published online: August 26, 2022

August 22, 2022

Non-invasive tests for evaluating treatment response in NAFLD

  • Heike Bantel,
  • Klaus Schulze-Osthoff
Published online: August 22, 2022

August 20, 2022

August 19, 2022

Partial MCT1 invalidation protects against diet-induced non-alcoholic fatty liver disease and the associated brain dysfunction

  • Anna Hadjihambi,
  • Christos Konstantinou,
  • Jan Klohs,
  • ...
  • Rajiv Jalan,
  • Rosa Chiara Paolicelli,
  • Luc Pellerin
Published online: August 19, 2022
Open Access

August 18, 2022

Ammonia - an old friend with a new area of application

  • Simon Johannes Gairing,
  • Leonard Kaps,
  • Eva Maria Schleicher,
  • Peter Robert Galle,
  • Christian Labenz
Published online: August 18, 2022

August 17, 2022

Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States

  • Xu Gao,
  • Fan Lv,
  • Xinyuan He,
  • ...
  • Yee Hui Yeo,
  • Fanpu Ji,
  • Mindie H. Nguyen
Published online: August 17, 2022

Secretin alleviates biliary and liver injury during late-stage primary biliary cholangitis via restoration of secretory processes

  • Lindsey Kennedy,
  • Guido Carpino,
  • Travis Owen,
  • ...
  • Heather Francis,
  • Shannon Glaser,
  • Gianfranco Alpini
Published online: August 17, 2022

August 16, 2022

SEAL: Why was this approach not effective?

  • Cristina Ripoll,
  • Jutta Bleidorn,
  • Alexander Zipprich
Published online: August 16, 2022

July 20, 2022

Advertisement